Le Lézard
Classified in: Health, Business
Subject: RCN

Sangamo Therapeutics Announces Technology Leadership Changes

RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the Company effective July 20th to pursue an opportunity with a startup biotech company. Edward Rebar, Ph.D., has been named Senior Vice President and Chief Technology Officer, effective immediately.

Sangamo Therapeutics, Inc. (PRNewsfoto/Sangamo Therapeutics, Inc.)

"We wish Michael well in his new endeavor," said Sandy Macrae, CEO of Sangamo. "We are grateful for his contributions to Sangamo over the years and are excited for him as he pursues this ground-floor opportunity at a biotech startup."

Dr. Holmes joined Sangamo in 2001 as a senior scientist and over the years has been promoted to lead many of Sangamo's research programs. Along with Dr. Rebar and other Sangamo scientists, Dr. Holmes made important contributions to the development of zinc finger proteins for therapeutic, research and agricultural applications. He was named Chief Technology Officer earlier in 2018.

Dr. Rebar joined Sangamo in 1998, and over the last 20 years he has led the development of the Company's zinc finger protein platform. He has authored over 60 publications relating to the development of customized DNA binding proteins and nucleases for genome editing.  Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley.  Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.

"I'm very pleased to announce Ed Rebar's promotion to Chief Technology Officer," Macrae said. "During his tenure at Sangamo, Ed has led the development and optimization of our core zinc finger technology. In the field of genome editing he is recognized as a leader and a strong voice for setting very high standards for editing technology being developed for therapeutic use."

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit the Company's website at www.sangamo.com.


SOURCE Sangamo Therapeutics, Inc.

These press releases may also interest you

at 18:26
The Penn Health Group groundbreaking ceremony celebrates the construction of its medical marijuana grower-processer facility in Lemont Furnace, Fayette County, PA. The Company was awarded a medical marijuana growing license from the State of...

at 18:22
TRUSTEEL, LLC ("TruSteel" or the "Company"), the creator and manufacturer of the AutoVaptm Series of falling-film evaporation technology, has finalized strategic alignment with pioneer technology integration firm Vanguard Scientific Systems. The...

at 18:18
Zeel, the Massage On Demand® company and national wellness provider, today announced it has partnered with Stride Health, the leading benefits platform for gig and independent workers, to offer the 11,000+ massage therapists on the Zeel platform...

at 18:10
Kane Biotech Inc. (the "Corporation" or "Kane Biotech") announces its Third Quarter 2018 Financial Results. Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that...

at 18:08
Copa Holdings, S.A. , today announced financial results for the third quarter of 2018 (3Q18). The terms "Copa Holdings" and "the Company" refer to the consolidated entity.  The following financial information, unless otherwise indicated, is presented...

at 18:02
After years of continuous month-over-month growth, IT employment dipped 0.02 percent in October, declining to 5,340,400 jobs, according to TechServe Alliance, the national trade association of the IT & Engineering Staffing and Solutions industry. On...

News published on 13 july 2018 at 16:15 and distributed by: